Dog dander allergen-specific immunoglobulin E (Dog sIgE) (Dog sIgE)

Dog dander allergen-specific immunoglobulin E (IgE) antibodies are the primary mediators of allergic reactions to dogs (Canis familiaris). These antibodies are produced by B cells in sensitized individuals and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (Source: NIH, PubMed). Upon exposure to dog allergens—such as the major lipocalin Can f 1 or the prostatic kallikrein Can f 5—the allergens cross-link the IgE-receptor complexes, triggering the rapid release of inflammatory mediators like histamine and leukotrienes (Source: World Allergy Organization). This physiological cascade leads to clinical symptoms including allergic rhinitis, conjunctivitis, and the exacerbation of atopic asthma (Source: StatPearls). Therapeutic strategies targeting these antibodies include monoclonal antibodies like Omalizumab, which sequester free IgE to prevent effector cell activation, and allergen immunotherapy (AIT), which aims to induce long-term immune tolerance (Source: Journal of Allergy and Clinical Immunology). Monitoring serum sIgE levels is a standard diagnostic approach for identifying dog-allergic patients and assessing the efficacy of therapeutic interventions (Source: Mayo Clinic).

Other names

Dog-specific IgECanis familiaris allergen-specific IgEAnti-dog dander IgE antibodiessIgE to dog allergens

Anti-IgE monoclonal antibodies sequester free circulating IgE, preventing its binding to high-affinity FcεRI receptors on mast cells and basophils; allergen immunotherapy (AIT) induces immune tolerance by shifting the Th2 response toward Th1/Treg and increasing allergen-specific IgG4 blocking antibodies (Source: PubMed, NIH).